US.VRTX · Vertex Pharmaceuticals

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.696774998857044,
        "turnoverUsdM": 481.921564324356,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.VRTX",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 457.9236,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 5.4,
      "take_profit_price": 508.2315,
      "target_multiplier": 1.6,
      "technical_strength": 1.48,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 5.393549997714088,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 66.3,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 59.3,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 480.302,
    "ma50": 471.9792,
    "close": 484.03,
    "prevClose": 484.83,
    "avgVolume20": 1338527,
    "volumeRatio": 0.74,
    "changePercent": -0.17
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.0048370125630678995,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.7141891843424742,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 0.8778842212711405,
      "volat_points": 0,
      "day_range_pct": 0.02321139396981889,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 66.3,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 3.8,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 76,
        "contribution": 3.8
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 9.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 61.33,
        "contribution": 9.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 6.8,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 68,
        "contribution": 6.8
      },
      {
        "raw": 20.7,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 69,
        "contribution": 20.7
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 59.3,
    "details": [
      "基本面分析總分: 3.8/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 9.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 6.8/10分",
      "技術信號分析總分: 20.7/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 3.8,
      "資金流": 10.8,
      "市場環境": 9.2,
      "情緒分析": 6,
      "技術信號": 20.7,
      "風險管理": 6.8
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "良好",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0.75,
          "debtPoints": 0.5,
          "marginPoints": 0.75,
          "turnoverUsdM": 481.921564324356,
          "volumePoints": 0.5,
          "revenuePoints": 0.4,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 1.6,
          "obvPoints": 4,
          "vwapPoints": 2.4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.VRTX",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "一般",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 700.4619942500001,
                "ma50": 714.69519954,
                "name": "QQQ",
                "close": 714.62,
                "points": 1
              },
              "spy": {
                "ma20": 749.25550215,
                "ma50": 746.7324035600001,
                "name": "SPY",
                "close": 768.53003,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.696774998857044,
          "atrPoints": 3,
          "cciPoints": 3.2,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              },
              {
                "id": 141106171,
                "url": "https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.",
                "category": "company",
                "datetime": 1785820106,
                "headline": "Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."
              },
              {
                "id": 141105354,
                "url": "https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...",
                "category": "company",
                "datetime": 1785798598,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141104290,
                "url": "https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785792601,
                "headline": "Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141104291,
                "url": "https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785792003,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"
              },
              {
                "id": 141103108,
                "url": "https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785789407,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"
              }
            ],
            "raw_source": [
              {
                "id": 141134178,
                "url": "https://finnhub.io/api/news?id=d3341145831fa1164ba72987649fc3f9cde6dfde5df1d47e24be44aed8cc7b65",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Study confirms western salt structure, identifies an eastern exploration target and establishes a staged technical pathway for further evaluationVANCOUVER, British Columbia, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce, further to its news release dated July 16, 2026, that it has received the final technical study prepared by Lonquist Field Service (Canada), ULC (“Lonquist”) for the Company’s Robinson",
                "category": "company",
                "datetime": 1786017600,
                "headline": "Vortex Energy Receives Final Technical Study Results for the Robinsons River Salt Project"
              },
              {
                "id": 141131676,
                "url": "https://finnhub.io/api/news?id=42acecf7bad1baa7ec04cb7ac59418a1c1004daf4cddd4cce6da65363ef901db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.",
                "category": "company",
                "datetime": 1785992501,
                "headline": "AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ..."
              },
              {
                "id": 141129231,
                "url": "https://finnhub.io/api/news?id=dcdf3ce3fb9a9978376d50e78da86431a8757aa1e827d9ec985228c198f4b841",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot flashes, associated with menopause. President and Chief Executive Officer Dr. Carl Hansen said enrol",
                "category": "company",
                "datetime": 1785967428,
                "headline": "AbCellera Biologics Q2 Earnings Call Highlights"
              },
              {
                "id": 141128774,
                "url": "https://finnhub.io/api/news?id=2a2a2d7e0c3b0c4acf97cdb30edff26305271e2d709137a8518fb82aaeb34cfe",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $560 to $565.",
                "category": "company",
                "datetime": 1785938692,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $565"
              },
              {
                "id": 141120403,
                "url": "https://finnhub.io/api/news?id=f62b2e86c4216e2bda2377255cef430a7f277cbdefbb4b3b2c17c9278e69b758",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc",
                "category": "company",
                "datetime": 1785927600,
                "headline": "Entrada Therapeutics Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141121678,
                "url": "https://finnhub.io/api/news?id=5248f37b608df4175afdacfec21505a887b9d7e62e088904934c0a4a097c8b4d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2288169175/image_2288169175.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.",
                "category": "company",
                "datetime": 1785924544,
                "headline": "CRISPR: \"Strong Buy\" CASGEVY Sales Growth And In Vivo Expansion With CTX310"
              },
              {
                "id": 141128775,
                "url": "https://finnhub.io/api/news?id=4a00fc07417e00a900782dede2c3227b5bb2ffd5494048eb5e0a007a66482462",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Barclays  analyst Eliana Merle   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $615 to $617.",
                "category": "company",
                "datetime": 1785922255,
                "headline": "Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $617"
              },
              {
                "id": 141111807,
                "url": "https://finnhub.io/api/news?id=e47001faa115166263a442f28230abdba42b95d19b8edb04e4fd9ecec1553469",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) remains well positioned heading into the second half of 2026 as severa",
                "category": "company",
                "datetime": 1785863115,
                "headline": "Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says"
              },
              {
                "id": 141111808,
                "url": "https://finnhub.io/api/news?id=1779ffa16d4cf28c1b259ac324be9f15ee814476b807b5bf97951a8231ca3e17",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reported a solid Q2 and raised its outlook, highlighting the strength",
                "category": "company",
                "datetime": 1785859337,
                "headline": "Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says"
              },
              {
                "id": 141110155,
                "url": "https://finnhub.io/api/news?id=ab934a24772cacbc2444176e33fe2e26a3432801ece501642cda46733319fe6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment.",
                "category": "company",
                "datetime": 1785855630,
                "headline": "How Vertex Regained Its Footing On A Competitor's Bullish Report"
              },
              {
                "id": 141111809,
                "url": "https://finnhub.io/api/news?id=c75088a93dadcf9e8e98257af8b682dac1d13336bde4d21c44821d1d977692b6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's Q2 earnings miss estimates, but revenues beat. It lifts its 2026 sales outlook, and sees growing contributions from newer products.",
                "category": "company",
                "datetime": 1785855420,
                "headline": "VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised"
              },
              {
                "id": 141110509,
                "url": "https://finnhub.io/api/news?id=f6f657f73b56d365c3988923bf6a3d9124e87491e39b6391d0a32defb58016c3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.",
                "category": "company",
                "datetime": 1785855360,
                "headline": "CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates"
              },
              {
                "id": 141110156,
                "url": "https://finnhub.io/api/news?id=f3baecf2b44e7c92410111d5cff7381e367457398aba185e3d320a8c7d034127",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises its 2026 revenue outlook as CF growth, newer products and a near-term renal launch strengthen its diversification push.",
                "category": "company",
                "datetime": 1785852000,
                "headline": "VRTX Q2 Earnings Call Highlights Launch Momentum & Higher Outlook"
              },
              {
                "id": 141120404,
                "url": "https://finnhub.io/api/news?id=536ca1939192aa75d5e6bab55534f6b569982fd11bc66824814b4cc31c74a4a9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Moby summary of Vertex Pharmaceuticals Incorporated's Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785846600,
                "headline": "Vertex Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141128776,
                "url": "https://finnhub.io/api/news?id=a0e8acf95ce40887b103881fce5237ca4516cca5aecd8d5b7c448a54203438f4",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.",
                "category": "company",
                "datetime": 1785846489,
                "headline": "TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550"
              },
              {
                "id": 141111811,
                "url": "https://finnhub.io/api/news?id=e0958b66343c41ec1dc90eccdc735fecb25accfdb235add8df6547d345ab61de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Despite another strong earnings report, analysts warned that upcoming cystic fibrosis data from Sionna Therapeutics \"looms large\" over Vertex.",
                "category": "company",
                "datetime": 1785845940,
                "headline": "Vertex’s biggest overhang: a rival 50 times smaller"
              },
              {
                "id": 141107841,
                "url": "https://finnhub.io/api/news?id=21c2ae1e0954cdae5c7b9195cab02ce3174708240085a53081522118a8c97864",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...",
                "category": "company",
                "datetime": 1785841838,
                "headline": "Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis"
              },
              {
                "id": 141107179,
                "url": "https://finnhub.io/api/news?id=06027c260ce9de9f61eb87edc3fd3f074dda0e76b30bcca2da7b0e57104fa68b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...",
                "category": "company",
                "datetime": 1785834837,
                "headline": "Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands"
              },
              {
                "id": 141110584,
                "url": "https://finnhub.io/api/news?id=83f00ed155351fa091931ebd6f19d490a2410a74beb0fca26cc0781a757d8552",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Cantor Fitzgerald  analyst Carter Gould   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.",
                "category": "company",
                "datetime": 1785831893,
                "headline": "Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595"
              },
              {
                "id": 141107416,
                "url": "https://finnhub.io/api/news?id=79c24c254426f5197e92c42652e8d662216c9656ed34db5290a7b518a70f7c0b",
                "image": "",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1785826663,
                "headline": "Vertex Pharmaceuticals: A Transition Year Into A Multi-Franchise Growth Story"
              },
              {
                "id": 141106171,
                "url": "https://finnhub.io/api/news?id=dd56684479086b09a9c08b3176c470d1855c316ea8c11773c551232e8fcd3c7d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex raises full-year 2026 revenue guidance to $13.1-$13.2 billion as CASGEVY and JOURNAVX show strong sequential growth, while advancing a robust pipeline and strategic Crinetics acquisition.",
                "category": "company",
                "datetime": 1785820106,
                "headline": "Vertex Pharmaceuticals Inc (VRTX) (Q2 2026) Earnings Call Highlights: Revenue Surges 12% to $3. ..."
              },
              {
                "id": 141105354,
                "url": "https://finnhub.io/api/news?id=7e00387653f41c77398a88e148bbf63751fee590b653e4f81ecdb065f240f8c5",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of...",
                "category": "company",
                "datetime": 1785798598,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141104289,
                "url": "https://finnhub.io/api/news?id=c7c1bac8a4be7e1bca887af4abc9e92a06d03ce636155d166171dc8851c4e126",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported second-quarter 2026 revenue growth of 12% year over year to $3.3 billion, driven by continued growth in its cystic fibrosis franchise and rising contributions from newer products CASGEVY and JOURNAVX. Chief Executive Officer and President Reshma Kewalra",
                "category": "company",
                "datetime": 1785798229,
                "headline": "Vertex Pharmaceuticals Q2 Earnings Call Highlights"
              },
              {
                "id": 141105291,
                "url": "https://finnhub.io/api/news?id=cd71711e25cb163c9f05f483851c9f5b6b7eb81c55fa46d409773ec5676efefb",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "2026-08-03. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q2 earnings call.",
                "category": "company",
                "datetime": 1785798079,
                "headline": "Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141104290,
                "url": "https://finnhub.io/api/news?id=2c85fd6651e8a37c93bd116754644b8c8fdc608ac20c6dd3606025ce523510da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785792601,
                "headline": "Vertex (VRTX) Reports Q2 Earnings: What Key Metrics Have to Say"
              },
              {
                "id": 141104291,
                "url": "https://finnhub.io/api/news?id=3312282938d1eebf9e011d1fbb4c0cede96428eca208a72aa3620cc06e6c5b8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785792003,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates"
              },
              {
                "id": 141103107,
                "url": "https://finnhub.io/api/news?id=98a2abcf301231bc0d0aaead7b8926e9c78fdfcb82c76cbbb0cc6e889ba5bb06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex stock dipped late Monday on a mixed second-quarter report. But the biotech giant raised its sales guidance for the year.",
                "category": "company",
                "datetime": 1785790435,
                "headline": "Vertex Raises 2026 Guidance, But Shares Dip For One Key Reason"
              },
              {
                "id": 141103108,
                "url": "https://finnhub.io/api/news?id=2107a32523531702676a61163a0ada3a64e71398d16b7a18148ca98956bb5707",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced better-than-expected revenue in Q2 CY2026, with sales up 12.5% year on year to $3.33 billion. The company’s full-year revenue guidance of $13.15 billion at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $4.73 per share was in line with analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785789407,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q2 CY2026 Sales Expectations, Full-Year Outlook Slightly Exceeds Expectations"
              },
              {
                "id": 141103109,
                "url": "https://finnhub.io/api/news?id=c2b5656a468d8791f71fe09a62a59cf02bfd34ac2e88a2aafd4178787e8d1233",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million for Second-Quarter 2026 SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumor",
                "category": "company",
                "datetime": 1785787500,
                "headline": "Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update"
              },
              {
                "id": 141103110,
                "url": "https://finnhub.io/api/news?id=b906634ef71b39efd517bbbaafd8f51cefd4da9cb3e99c193c693beb458b10fa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, August 03, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2026, and updated its full year 2026 revenue guidance.",
                "category": "company",
                "datetime": 1785787260,
                "headline": "Vertex Reports Second Quarter 2026 Financial Results"
              },
              {
                "id": 141102404,
                "url": "https://finnhub.io/api/news?id=939a925a360f140b82437bcf1c066f9578c7f6d8d02242dd6344b422c5f7a75f",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.",
                "category": "company",
                "datetime": 1785772904,
                "headline": "Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est"
              },
              {
                "id": 141102405,
                "url": "https://finnhub.io/api/news?id=d851715324594ca0a83a36932e5f194d1100c4a171088992edaa84adad7f327d",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last",
                "category": "company",
                "datetime": 1785772886,
                "headline": "Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate"
              },
              {
                "id": 141101633,
                "url": "https://finnhub.io/api/news?id=210dc9eadb0f1e641b405b20d701188a86b5d7a5db961e15cc5ee67a2573203c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231767274/image_2231767274.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Big Tech's earnings reports laid bare a growing divide in the market's appetite for AI spending. Investors now focus on results from industrials, health care, consumer staples/discretionary.",
                "category": "company",
                "datetime": 1785766800,
                "headline": "Divided Tech, Divided Fed: Navigating AI Capex Scrutiny And Mixed Macro Signals"
              },
              {
                "id": 141098887,
                "url": "https://finnhub.io/api/news?id=48d0b35462c58b56f76fb282a857a48a7324ea7d8a8bec1032ce82a8f07a63bf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wall Street futures pointed moderately higher pre-bell Monday after President Donald Trump, over the",
                "category": "company",
                "datetime": 1785755481,
                "headline": "Falling Oil Boosts Wall Street Pre-Bell; Asia Mixed, Europe Up"
              },
              {
                "id": 141099604,
                "url": "https://finnhub.io/api/news?id=0b813f41b7078cecf12b4aafa9a2ca131b75aa021fa9c19c50adbd14d08635cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/TysonFoods.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.",
                "category": "company",
                "datetime": 1785724052,
                "headline": "Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday"
              },
              {
                "id": 141100201,
                "url": "https://finnhub.io/api/news?id=bad502596ada943e824fa1a41cadb663072846cc663445ce8eab7c42d8dbcca9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/03/Fear-and-Greed.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.",
                "category": "company",
                "datetime": 1785723704,
                "headline": "Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone"
              },
              {
                "id": 141091494,
                "url": "https://finnhub.io/api/news?id=fab83185dfc322c5138a32b43f26849a509ecd83026c58227dad50ddfd0cb7aa",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what to look for.",
                "category": "company",
                "datetime": 1785645417,
                "headline": "Vertex Pharmaceuticals (VRTX) Q2 Earnings Report Preview: What To Look For"
              },
              {
                "id": 141081582,
                "url": "https://finnhub.io/api/news?id=fbee925dabbe6f460ef2b4b28c54e17bf35b8224f7677ab26790e7608838499f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.",
                "category": "company",
                "datetime": 1785526149,
                "headline": "Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?"
              },
              {
                "id": 141072827,
                "url": "https://finnhub.io/api/news?id=eb8ae6cb70ca7b946707a8aa4b6c4d3c77225f489baa605fe36f3ca8cc64e515",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "There are other reasons to pay attention to Viking Therapeutics.",
                "category": "company",
                "datetime": 1785451800,
                "headline": "Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target"
              },
              {
                "id": 141057143,
                "url": "https://finnhub.io/api/news?id=421d31ea5999d389b5893a796c7ed1557f77b278da24643c864ae1a8d7df7f3a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) is back in focus after AbCellera Biologics announced a collaboration to develop multispecific T cell engagers targeting autoimmune diseases and other conditions. Under the agreement, Vertex will fund the research and retain commercialization rights. See our latest analysis for Vertex Pharmaceuticals. The latest AbCellera collaboration comes as Vertex Pharmaceuticals' share price has risen 15.87% over the past 90 days and the 5 year total shareholder return sits...",
                "category": "company",
                "datetime": 1785352120,
                "headline": "Vertex Pharmaceuticals (VRTX) Expands Its Pipeline Reach, Is The Stock Fully Valued?"
              },
              {
                "id": 141055852,
                "url": "https://finnhub.io/api/news?id=af8516feb80f1c0c63d5e073b11c8faedae64310cc396f9cbb7780cbc28736e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals has delivered a 145.1% return over the past five years, yet its current valuation picture is mixed, as a Discounted Cash Flow (DCF) intrinsic value estimate points to meaningful upside while market-based multiples look closer to fair. Over five years, Vertex Pharmaceuticals has returned 145.1%, which puts the current share price in a very different place compared with where long-term holders started. Expectations for continued cash generation from its existing...",
                "category": "company",
                "datetime": 1785341297,
                "headline": "Vertex Pharmaceuticals (VRTX) Stock Looks Like A Bargain At This Price"
              },
              {
                "id": 141054235,
                "url": "https://finnhub.io/api/news?id=ec84f806f9b56e49cb76104e77c2ce400a7ef3f40a464d06bfad72fa6a3adbbf",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Evaluate the expected performance of Vertex (VRTX) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",
                "category": "company",
                "datetime": 1785330924,
                "headline": "Vertex (VRTX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates"
              },
              {
                "id": 141054236,
                "url": "https://finnhub.io/api/news?id=de94bed6584f5074d58e85040ba27013c8626725d9b5c8153c69645b52623247",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.",
                "category": "company",
                "datetime": 1785325200,
                "headline": "AbCellera, Vertex partner on next-gen T-cell engagers"
              },
              {
                "id": 141052195,
                "url": "https://finnhub.io/api/news?id=60bbb3013ffab29675f18d6859109afcd760881dfa67d13bb4615ac423d1506e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, July 29, 2026--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions",
                "category": "company",
                "datetime": 1785322800,
                "headline": "AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions"
              },
              {
                "id": 141051677,
                "url": "https://finnhub.io/api/news?id=58593945567739718700c0a3f06ba07fe7dd080a3f1abae5a528f461dd26e8eb",
                "image": "https://www.chartmill.com/images/uploads/Strong_Growth_500_264px_webp_8f1ee6ba5b.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) combines strong earnings growth, zero debt, and a consolidating technical pattern, making it a textbook breakout candidate for growth investors.",
                "category": "company",
                "datetime": 1785319828,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth and Textbooks Technical Setup for Breakout"
              },
              {
                "id": 141048348,
                "url": "https://finnhub.io/api/news?id=7172b274a14c0e365b0221f98cf8730f87f861736eeece3e6e1d313c5bc1f022",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.",
                "category": "company",
                "datetime": 1785275405,
                "headline": "Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider"
              },
              {
                "id": 141043741,
                "url": "https://finnhub.io/api/news?id=7f74e4b608d0430ce273cd33af9179a12f910b9aa7dd3269cbb77c4b0b1085f6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785247226,
                "headline": "Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 141043769,
                "url": "https://finnhub.io/api/news?id=b7dde44202e682107701df8a3cf25cac7d7d55413e6642c4ec20852be2744635",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "category": "company",
                "datetime": 1785243604,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know"
              },
              {
                "id": 141044941,
                "url": "https://finnhub.io/api/news?id=85487e655fb89144a8a6f022c19cdb5c978e7d32417f8c31520957270297579f",
                "image": "https://image.cnbcfm.com/api/v1/image/108340810-260727-Chris_Young__Vertex_CEO.jpg?v=1785190743&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Vertex CEO Chris Young told Jon Fortt tax compliance is being remade by AI, e-invoicing mandates and agentic commerce – but tax has to stay deterministic, so AI wraps the engines rather than replacing them. He's targeting $60–70M in savings to fund that shift. Young grew up working class on Cleveland's east side, a Great Migration family – father in autos, mother working three jobs – before Princeton and a career at AOL, McAfee and Microsoft.",
                "category": "company",
                "datetime": 1785234037,
                "headline": "Chris Young, Vertex CEO: A Fortt Knox Conversation"
              },
              {
                "id": 141035245,
                "url": "https://finnhub.io/api/news?id=907644a0468d61ac054182ce249d9a1ef85614834d4d246abe2d6b7ed023a0a1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.",
                "category": "company",
                "datetime": 1785166320,
                "headline": "Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?"
              },
              {
                "id": 141033946,
                "url": "https://finnhub.io/api/news?id=75ff07118ffa82f1c08f586e8d6232740ba903a6eddbecfca1b3be71d8f36219",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1785160812,
                "headline": "Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?"
              },
              {
                "id": 141010849,
                "url": "https://finnhub.io/api/news?id=61caf6cd2d1aa2c47d5b115b8acad8415f768278eafa34f312a4ded1833d3fa7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "VANCOUVER, British Columbia, July 24, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has engaged MCS Market Communication Service GmbH (“MCS”) (address: Rheinpromenade 13, 0789 Monheim am Rhein; email: info@mcsmarket.de) to provide marketing services for an expected term of 3 months, commencing July 27, 2026, provided that the term of the marketing services may be extended or shortened at the discretion of management",
                "category": "company",
                "datetime": 1784926800,
                "headline": "Vortex Energy Corp. Announces Marketing Program"
              },
              {
                "id": 140994788,
                "url": "https://finnhub.io/api/news?id=531056513eb02609f4a4938c9a9d323461a433a76b4cbd553c5d298c12047e7a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its first drug on the market and a pipeline full of catalysts, the company asks investors to weigh a powerful growth story against an elevated valuation and a history of volatility.",
                "category": "company",
                "datetime": 1784818856,
                "headline": "Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?"
              },
              {
                "id": 140992567,
                "url": "https://finnhub.io/api/news?id=f03ef675567d5108e942c33fea0af0f892d3babe234791d60ea6de7bc0d32119",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 10%, nearly mirroring the S&P 500.",
                "category": "company",
                "datetime": 1784802168,
                "headline": "3 Healthcare Stocks with Competitive Advantages"
              },
              {
                "id": 140989341,
                "url": "https://finnhub.io/api/news?id=9a4acf17d85cd62640b1ef99d26433eb4843ddd26ea54db4439b95b95e06927d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.",
                "category": "company",
                "datetime": 1784757004,
                "headline": "Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know"
              },
              {
                "id": 140988043,
                "url": "https://finnhub.io/api/news?id=4e6b58aa0243c4cf3ed6fa01c255ff8093c21f5501c6043b24f8e69611512bd7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Analysts expect new details on the lead-up to the deal “are likely to reignite” investor scrutiny that Vertex overpaid in what’s poised to be its largest-ever transaction.",
                "category": "company",
                "datetime": 1784738880,
                "headline": "Vertex was sole bidder in high-premium Crinetics acquisition"
              },
              {
                "id": 140975311,
                "url": "https://finnhub.io/api/news?id=25ea968d0976819831cb67877ca7d310eb561e52b6e6376eb848ef60154d12c1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/21/Russell-2000-Index--Text-On-Notebook-Wit.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.",
                "category": "company",
                "datetime": 1784649148,
                "headline": "These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why"
              },
              {
                "id": 140970568,
                "url": "https://finnhub.io/api/news?id=17b796c52376fef7d61ed6758f543a5b5122e8be4093a5b173e2914f2be71336",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(American News Group News Commentary) For the millions of people who manage diabetes with daily insulin injections, the holy grail has always been the same: a therapy that senses blood sugar and releases the right amount of insulin on its own, the way a healthy pancreas does. A growing group of biotech companies is chasing that goal with cell-based therapies, and this week one small player took a concrete step toward making its version real.",
                "category": "company",
                "datetime": 1784638800,
                "headline": "A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up"
              },
              {
                "id": 140970448,
                "url": "https://finnhub.io/api/news?id=4a0e1ac981bb5a7f38fee8acbaf68052de3d913022a498bdaffa2648573b9719",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam",
                "category": "company",
                "datetime": 1784637325,
                "headline": "Biotech IPO Gains Crush AI Listings With Standout 55% Return"
              },
              {
                "id": 140969778,
                "url": "https://finnhub.io/api/news?id=27a8f9b4c11fb3341b7a9d59fe254f0b38844816434279378c40ce04a712ba81",
                "image": "https://www.chartmill.com/images/uploads/Affordable_Growth_500_264px_webp_add6a3aa59.webp",
                "source": "ChartMill",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals offers affordable growth with strong double-digit earnings and revenue expansion, zero debt, and a P/E below the S&P 500 average—trading at a deep discount to biotech peers.",
                "category": "company",
                "datetime": 1784636429,
                "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation"
              },
              {
                "id": 140966272,
                "url": "https://finnhub.io/api/news?id=873f6ef6e8863740f15f5ee5dac12b06b5a4bce91785b0cbcd6cc716a92c8621",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the preceding trading day.",
                "category": "company",
                "datetime": 1784584806,
                "headline": "Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today"
              },
              {
                "id": 140958171,
                "url": "https://finnhub.io/api/news?id=92d5092f112f44af843f3884d48faf9004532046bab42282250b2a22dc512f2d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Earlier this month, the FDA expanded approval of Vertex Pharmaceuticals’ gene therapy Casgevy (exagamglogene autotemcel) to children aged 2 and older with sickle cell disease and transfusion-dependent thalassemia, following strong efficacy signals in two small pediatric trials. This milestone meaningfully widens access to a first-in-class gene therapy for very young patients, reinforcing Vertex’s role in genetic medicines beyond its cystic fibrosis core. We’ll examine how broadening...",
                "category": "company",
                "datetime": 1784538570,
                "headline": "How FDA’s Pediatric Expansion of Casgevy at Vertex Pharmaceuticals (VRTX) Has Changed Its Investment Story"
              },
              {
                "id": 140957169,
                "url": "https://finnhub.io/api/news?id=eff47664a09c223d3bd87244ea256a86d7edb50f9be4a91c0183fbb81ead926f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals' gene therapy exagamglogene autotemcel (Casgevy) has received expanded FDA approval. The approval now includes children as young as 2 years old with sickle cell disease or transfusion-dependent thalassemia. This decision broadens treatment options for a pediatric group with limited alternatives. For investors watching NasdaqGS:VRTX, the expanded approval highlights how Vertex Pharmaceuticals is building out its rare disease franchise around genetic medicines. The...",
                "category": "company",
                "datetime": 1784524037,
                "headline": "Vertex Pharmaceuticals (VRTX) Wins FDA Nod To Treat Children As Young As 2"
              },
              {
                "id": 140956306,
                "url": "https://finnhub.io/api/news?id=83d73f2ff98d0ae97212a4f0871c30b3aa6f32ee58d242286e4e3a28433d61cd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The biotech's diversification efforts continue.",
                "category": "company",
                "datetime": 1784505900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching"
              },
              {
                "id": 140921040,
                "url": "https://finnhub.io/api/news?id=b38cca16ff3fdab553b9d5e5467ff26d8301f3f124e2c0c76e4b155de1bc8e82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The Nasdaq 100 (^NDX) is home to some of the biggest success stories in tech and growth investing. However, certain stocks in the index face challenges like profitability concerns, rising costs, or shifts in market trends.",
                "category": "company",
                "datetime": 1784214322,
                "headline": "1 Nasdaq 100 Stock to Keep an Eye On and 2 We Question"
              },
              {
                "id": 140919919,
                "url": "https://finnhub.io/api/news?id=ac38e40815783f8ec5171d72b4c86aa0d5496672e10888f4bb0f5347b866864d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1784207177,
                "headline": "Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140921115,
                "url": "https://finnhub.io/api/news?id=c30edaca5af32f3105a0567a5af374e6b5c51828db4fe6b490b1d148d2a5a47e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
                "category": "company",
                "datetime": 1784206803,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It"
              },
              {
                "id": 140919920,
                "url": "https://finnhub.io/api/news?id=22f201450e4146a22e8d333752623c653c83dfc64ed8ec26c95bd36b95ee5206",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Technical review to strengthen subsurface model and guide next phase of developmentVANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to provide a corporate update on the ongoing technical study being completed by Lonquist Field Service (Canada), ULC (“Lonquist”) at the Company’s Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoun",
                "category": "company",
                "datetime": 1784203200,
                "headline": "Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study"
              },
              {
                "id": 140918684,
                "url": "https://finnhub.io/api/news?id=c5cd568c38c82229699ecfeff65d5f3e8af22b1b318f0d131623d8f2582c384d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190808580/image_2190808580.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "The curing sickle cell through gene therapy story is a long way from being written. But it’s for sure that it has not gone like some of its participants have wanted it to. Read more here...",
                "category": "company",
                "datetime": 1784187000,
                "headline": "The Battle For Sickle Cell"
              },
              {
                "id": 140925193,
                "url": "https://finnhub.io/api/news?id=a1e97ddb4115cd5f851ad1b2dcb8625c247944437da76f2f5a37275be9ebfa7d",
                "image": "https://cdn.benzinga.com/files/images/story/2025/07/10/valuestock_4.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market",
                "category": "company",
                "datetime": 1784135733,
                "headline": "$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today"
              },
              {
                "id": 140911439,
                "url": "https://finnhub.io/api/news?id=a706d9b34a32e9ee4e72c8bb0e5c93ecc188bc198255ecbd232c037a410bf5d7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "An ETF's label tells you the category, but the real story is always in the portfolio's actual shape.",
                "category": "company",
                "datetime": 1784132585,
                "headline": "IBB ETF Holds Fewer Bets Than You Think"
              },
              {
                "id": 140909807,
                "url": "https://finnhub.io/api/news?id=894eb83bae3b7701338821979d336d28e14b5029ab6a7dc8a0330d7df2b3d9fb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is one of the 10 affordable biotech stocks to buy right now. On July 6, Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Vertex Pharmaceuticals announced that both companies have agreed to a definitive agreement, according to which Vertex will acquire Crinetics Pharmaceuticals. The deal is priced at $85 a share in cash consideration, […]",
                "category": "company",
                "datetime": 1784124103,
                "headline": "Vertex to Acquire Crinetics Pharmaceuticals (CRNX) in $85 Per Share Cash Deal"
              },
              {
                "id": 140897048,
                "url": "https://finnhub.io/api/news?id=8fd522063fde651778f609334b93b87ac175d51b99792eac01e61e5ec2bdd003",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex's $10 billion acquisition may have spooked investors, given how rich it appeared to be.",
                "category": "company",
                "datetime": 1784031600,
                "headline": "Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals"
              },
              {
                "id": 140892612,
                "url": "https://finnhub.io/api/news?id=3d6b8baa9a83aa76e7cac3b939b0b62322f2dc6cbddd01beda9acf03fcca2fe6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.",
                "category": "company",
                "datetime": 1783980006,
                "headline": "Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors"
              },
              {
                "id": 140891369,
                "url": "https://finnhub.io/api/news?id=cd9d911d1d1ddc04410b592e494aed229ad87f0921faa2794983c8582dbd1465",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces that it has closed its previously announced non-brokered private placement financing (the “Private Placement”). The Company issued an aggregate of 5,000,000 units of the Company (the “Units”) at a price of $0.30 per Unit for gross proceeds of $",
                "category": "company",
                "datetime": 1783979160,
                "headline": "Vortex Energy Corp. Announces Closing of LIFE Offering"
              },
              {
                "id": 140889916,
                "url": "https://finnhub.io/api/news?id=e8a7de07cc162dea1ae6251224928f62de69baad025c1e8b989c861cc24f2a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals recently announced its largest-ever acquisition.",
                "category": "company",
                "datetime": 1783968427,
                "headline": "Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?"
              },
              {
                "id": 140891092,
                "url": "https://finnhub.io/api/news?id=7de8e9d2f4590eeb57173c106d795ec9e57e4287831ea47e3a3f0eb5dc45f49e",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "UBS  analyst Michael Yee   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.",
                "category": "company",
                "datetime": 1783952283,
                "headline": "UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585"
              },
              {
                "id": 140891370,
                "url": "https://finnhub.io/api/news?id=03bcc91f3ed155fa3ddcb91bbc261b06b7a6a3b1554a720faace2ae6851096e3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.",
                "category": "company",
                "datetime": 1783951045,
                "headline": "What to Expect From Vertex Pharmaceuticals' Next Quarterly Earnings Report"
              },
              {
                "id": 140891093,
                "url": "https://finnhub.io/api/news?id=fd93aff66889dc24055c8b99639e5acc340f6629383543951e341c24f0b63207",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Truist Securities  analyst Danielle Brill   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $542 to $560.",
                "category": "company",
                "datetime": 1783945862,
                "headline": "Truist Securities Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $560"
              },
              {
                "id": 140874823,
                "url": "https://finnhub.io/api/news?id=74393636e844e518614a2f2bbc4b00f4b95cda8bb29e624da6373305bfa8aab5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) received expanded FDA approval for CASGEVY, extending use to children as young as 2 years with sickle cell disease and beta thalassemia. The company also signed a Letter of Intent with Canadian national payers that outlines commercial access terms for ALYFTREK, its next generation cystic fibrosis therapy. These updates arrive as Vertex Pharmaceuticals trades around $485.39 and remains closely watched after a 140.0% return over the past 5 years and a...",
                "category": "company",
                "datetime": 1783826346,
                "headline": "Vertex (VRTX) Wins FDA Expansion For CASGEVY And Advances ALYFTREK In Canada"
              },
              {
                "id": 140873536,
                "url": "https://finnhub.io/api/news?id=e9086ad552f75890511f4f50816a1086a025168d4d5bcc85a6530a23c82a78c6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology. On a conference call announcing the deal, Vertex CEO",
                "category": "company",
                "datetime": 1783803729,
                "headline": "Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse"
              },
              {
                "id": 140866271,
                "url": "https://finnhub.io/api/news?id=3474024df282bf83c2487827c06844fbdf81b888de20d743220ca244b809d07e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It's been a volatile year for the company, but don't let that scare you away.",
                "category": "company",
                "datetime": 1783718400,
                "headline": "Is This Biotech Stock a Buy Near Its 52-Week High?"
              },
              {
                "id": 140865211,
                "url": "https://finnhub.io/api/news?id=c9b07089322e23d06265dae52c2992c333bdcda8fef02ebe98f458bef38d5d1f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "It is getting acquired by a larger firm in the sector.",
                "category": "company",
                "datetime": 1783711352,
                "headline": "Why This Pharmaceutical Stock Jumped Close to 100% This Week"
              },
              {
                "id": 140861703,
                "url": "https://finnhub.io/api/news?id=af70857a11cc855d135aa4dbacdfb09561eefbc7830e6114b9d2980a93d0ad6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.",
                "category": "company",
                "datetime": 1783686601,
                "headline": "If You Invested $1000 in Vertex Pharmaceuticals a Decade Ago, This is How Much It'd Be Worth Now"
              },
              {
                "id": 140861704,
                "url": "https://finnhub.io/api/news?id=261335ddb3a4405ad09573cc88858404a83f044cb91dc30fe6fb403e911b1373",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "With its lead drug driving rapid growth and three more on deck, the biotech is betting it can outrun future competition and a history of volatility.",
                "category": "company",
                "datetime": 1783685653,
                "headline": "Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?"
              },
              {
                "id": 140860831,
                "url": "https://finnhub.io/api/news?id=70bace5e39146e0e64ac0773b15c6a491cc88cb329eb3be14cd2305070834fcd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "A look at the company's history of deep drawdowns shows the real risk shareholders are carrying today.",
                "category": "company",
                "datetime": 1783683335,
                "headline": "The Long Climb Back For Ionis Stock"
              },
              {
                "id": 140859839,
                "url": "https://finnhub.io/api/news?id=cdd9c810230d73c852b260a9d4bceec99d4b0eebc8f9e6457c65267d2e0ad5c7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Additional blockbuster drugs may be on the horizon.",
                "category": "company",
                "datetime": 1783671900,
                "headline": "Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?"
              },
              {
                "id": 140854805,
                "url": "https://finnhub.io/api/news?id=73dd4ee0879bf24374581d5aa1a77260cfbe8b63a6339577b193b70be26a497b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NASDAQ:VRTX) is one of the best QQQ Stocks to invest in. On July 1, Vertex Pharmaceuticals announced that the US FDA approved the expanded use of its genetic therapy, CASGEVY, to treat children as young as 2 years old. This makes it the first and only approved gene therapy for patients of this […]",
                "category": "company",
                "datetime": 1783622227,
                "headline": "Vertex (VRTX) is One of the Best QQQ Stocks to Invest in"
              },
              {
                "id": 140853379,
                "url": "https://finnhub.io/api/news?id=af8f4e5d4bf20131bde841c0314c7a25c154ef1a511b44e077f6a59cd29c3986",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX) agreed to acquire it. Vertex’s $10 Billion All-Cash Bid Fuels the Surge The catalyst arrived after the market close on July 6: Vertex agreed to buy Crinetics for approximately $10 ... Why Crinetics Stock Soared 99% This Week",
                "category": "company",
                "datetime": 1783618179,
                "headline": "Why Crinetics Stock Soared 99% This Week"
              },
              {
                "id": 140852010,
                "url": "https://finnhub.io/api/news?id=553e10dc88f8db461878d38f0666f117101c8f854c6a22e5273fb7ce1784b80d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech that we have not talked about at all that is really extraordinary, and particularly since the change at the head of the FDA,” ... Jim Cramer Says Biotech is The Hottest Group in The Market Right Now",
                "category": "company",
                "datetime": 1783611325,
                "headline": "Jim Cramer Says Biotech is The Hottest Group in The Market Right Now"
              },
              {
                "id": 140852138,
                "url": "https://finnhub.io/api/news?id=ff73aa141d7117de4953b3a8c5dac95fb022c08cd27a3ad995d33e371ff05606",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The cystic fibrosis market is expanding due to rising disease prevalence and advancements in targeted therapies and precision medicine. Predominantly affecting Western populations, over 30,000 people in the U.S. live with this genetic disorder. The demand for cystic fibrosis therapies is driven by new treatments and an aging population. CFTR modulator therapies have significantly improved patient outcomes by targeting mutations in the CFTR gene. While novel treatments provide hope, high costs an",
                "category": "company",
                "datetime": 1783610760,
                "headline": "Cystic Fibrosis Market, Global & Regional Now Available; Profiles Vertex Pharmaceuticals, AbbVie, and Other Frontrunner Competitors in Orphan Drug Markets"
              },
              {
                "id": 140859174,
                "url": "https://finnhub.io/api/news?id=c227e9fb11d31a3021a091175fdb43fac55c743eccee1f8a273f64ab8ad8c2db",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a structural dynamic: most new drugs now originate from biotech, while large pharmaceutical companies face a significant wave of patent expiries and hold substantial cash resources. Vertex's move into rare diseases and chronic therapies makes strategic sense as it diversifies beyond its cystic fibrosis franchise — and the premium paid reflected Crinetics' strong independent position. \"They would be perfectly happy to stay independent. And Vertex had to pay up if they wanted to buy them,\" Craig said. She outlined how IBT evaluates investments using many of the same criteria as pharma business development teams — focusing on chronic therapies, attractive valuations, strong intellectual property and companies capable of remaining independent, making them compelling acquisition targets. Around 40% of IBT's portfolio currently meets these criteria, compared with around 10% of its benchmark - a positioning Craig believes leaves the trust well placed to benefit from continued industry consolidation. Visit the Proactive YouTube channel for more interviews with leading companies and investment experts. If you enjoyed this video, please like, subscribe to the channel and enable notifications so you never miss future content. #InternationalBiotechnologyTrust #Biotech #Biotechnology #AilsaCraig #HealthcareInvesting #BiotechStocks #Pharma #Vertex #Crinetics #MergersAndAcquisitions #Investing #StockMarket #LifeSciences #PatentExpiry #HealthcareInnovation #ProactiveInvestors",
                "category": "company",
                "datetime": 1783599944,
                "headline": "IBT portfolio manager: biotech M&A boom set to continue as big pharma hunts"
              },
              {
                "id": 140848791,
                "url": "https://finnhub.io/api/news?id=7d568a47c8ad16b91d73b1c96aa5bfe5a734482183673771b763e535d2afd1c4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.",
                "category": "company",
                "datetime": 1783583340,
                "headline": "1 Momentum  Stock to Research Further and 2 Facing Headwinds"
              },
              {
                "id": 140851993,
                "url": "https://finnhub.io/api/news?id=10ee6961d749320bbe6f5493aa7cd89e579980c9c25c75c0a3637ceb4d7cec88",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/09/Nvidia-logo-on-smartphone-screen-with-Ch.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "The Halftime Report Final Trades featured stock picks from Bryn Talkington, Jim Lebenthal, Liz Young Thomas, and Joseph M. Terranova.",
                "category": "company",
                "datetime": 1783583115,
                "headline": "Nvidia, Vertex Pharmaceuticals And More On CNBC’s ‘Final Trades’"
              },
              {
                "id": 140847591,
                "url": "https://finnhub.io/api/news?id=b51355813fb0db28e4890bf556e8770afbd41f58f0985074d5473b6d81753f73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Penguin Solutions, Arista Networks, and Biocryst Pharmaceuticals surged to 52-week highs on Wednesday amid a rotation into technology and healthcare stocks.",
                "category": "company",
                "datetime": 1783568379,
                "headline": "Why Did PENG, ANET, BCRX Shares Surge To 52-Week Highs?"
              },
              {
                "id": 140841649,
                "url": "https://finnhub.io/api/news?id=46cf1067762772bdaff0bf3cd43eb85b6816d116b9c6119f06b2aaa77d698dba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather th",
                "category": "company",
                "datetime": 1783523510,
                "headline": "Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says"
              },
              {
                "id": 140841830,
                "url": "https://finnhub.io/api/news?id=496b1ff88d3330c5cf8f0e9db6cf6769f8a09a0ceae7d543fd0f2e908dbb4915",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the best healthcare stocks on our list. TheFly reported on July 2 that UBS analyst Ashwani Verma initiated coverage of CRNX with a Buy rating and a $55 price target. The analyst noted that […]",
                "category": "company",
                "datetime": 1783523080,
                "headline": "Is Crinetics Pharmaceuticals, Inc. (CRNX) Stock a Buying Opportunity After a 44% Pullback?"
              },
              {
                "id": 140842715,
                "url": "https://finnhub.io/api/news?id=c8f467e1ed158fcec22bad8db27051c262b7c5c889f593124c45188044a6eec0",
                "image": "https://image.cnbcfm.com/api/v1/image/108332237-17835306111783530602-47038414389-1080pnbcnews.jpg?v=1783530610&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Mike Akins, ETF Action founding partner, joins 'Halftime Report' to discuss the under-appreciated market trades, catch up trades for the rest of the year and much more.",
                "category": "company",
                "datetime": 1783516859,
                "headline": "Software and cloud computing names have strong growth scenarios, says ETF Action's Mike Akins"
              },
              {
                "id": 140840572,
                "url": "https://finnhub.io/api/news?id=c206e2009193c9aaa77cf09239f7c877b0a9f0a5dffa3fef4e2ae51a1758d667",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals stock has delivered a strong 163.3% return over the past 5 years, and the latest Discounted Cash Flow (DCF) intrinsic value estimate now points to meaningful upside relative to the current share price, even though market based valuation checks look more balanced. Over 5 years, a 163.3% total return suggests investors have already priced in a lot of success for Vertex Pharmaceuticals, which raises the bar for any further potential upside. The planned US$10b acquisition...",
                "category": "company",
                "datetime": 1783516331,
                "headline": "Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal"
              },
              {
                "id": 140842570,
                "url": "https://finnhub.io/api/news?id=ee1ffe5e8d5a6325b6d11f969a0327c5fedc224009f46d9e761ed327ef11e409",
                "image": "https://image.cnbcfm.com/api/v1/image/108332231-17835301031783530100-47038298545-1080pnbcnews.jpg?v=1783530102&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "The Investment Committee give you their top stocks to watch for the second half.",
                "category": "company",
                "datetime": 1783515957,
                "headline": "Final Trades: Vertex, Nvidia, the DRAM and the VNQ"
              },
              {
                "id": 140851013,
                "url": "https://finnhub.io/api/news?id=da4341664338040440e42f161261d5e9008e268c4ca8a1137f20bf5b9e730807",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals will acquire Crinetics Pharmaceuticals for $10 billion at $85 per share, adding the approved drug PALSONIFY and pipeline candidate Atumelant to expand beyond its cystic fibrosis franchise.",
                "category": "company",
                "datetime": 1783515900,
                "headline": "Vertex’s Crinetics Deal Balances Growth with Integration Risk"
              },
              {
                "id": 139934456,
                "url": "https://finnhub.io/api/news?id=188b4d8ee71a8e52b66809d406cc7c293d8b00b7f1c9f28a4df221dd0b53d09c",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "",
                "category": "company",
                "datetime": 1783515679,
                "headline": "Hesai Says Co Selected By NVIDIA As Lidar Partner For NVIDIA DRIVE Hyperion 10"
              },
              {
                "id": 140840573,
                "url": "https://finnhub.io/api/news?id=5e139a297017ff79fead3a17df77dd2984859059085fd34751ce71e2a30a986a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Get paid a guaranteed income on your Vertex shares today, which you keep no matter what, for agreeing to sell them at a higher price if the stock keeps climbing.",
                "category": "company",
                "datetime": 1783514909,
                "headline": "Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside"
              },
              {
                "id": 140840574,
                "url": "https://finnhub.io/api/news?id=f820520193374e48e28b94a6e505d718214ae560811fdc586e1e0d09fff0c376",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) has moved into the spotlight after agreeing to acquire Crinetics Pharmaceuticals for about $10 billion in cash, a rare disease focused deal that immediately broadens its endocrinology footprint. See our latest analysis for Vertex Pharmaceuticals. Vertex Pharmaceuticals' latest share price of US$522.25 sits close to recent highs, with a 30 day share price return of 16.88% and a 1 year total shareholder return of 11.98%, adding to a 163.32% total shareholder return...",
                "category": "company",
                "datetime": 1783512691,
                "headline": "Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now?"
              },
              {
                "id": 140838993,
                "url": "https://finnhub.io/api/news?id=093edf349b6b567d5c293f0ac8a8491b0d399e592d30167978955680c4d1379b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for about US$10b, reigniting takeover speculation across the obesity drug sector. Following this deal, Viking Therapeutics (NasdaqCM:VKTX) has drawn fresh attention as a possible M&A target. Investor focus is increasing on upcoming data for VK2735 and the recently initiated Phase 1 trial of VK3019. Viking Therapeutics sits at the intersection of obesity and metabolic drug development, an area that has attracted large capital...",
                "category": "company",
                "datetime": 1783501955,
                "headline": "Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal"
              },
              {
                "id": 140838994,
                "url": "https://finnhub.io/api/news?id=42e20c4f78b5d7fa6b079afa6f31b4bfe9537928845ffa1814e1302bc78586e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.",
                "category": "company",
                "datetime": 1783496933,
                "headline": "Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It."
              },
              {
                "id": 140838995,
                "url": "https://finnhub.io/api/news?id=2302cd588f2b9ed71e70e8e266ac65567ea81fef90aa851924a7e09285d9f136",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "CRINETICS PHARM (CRNX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.",
                "category": "company",
                "datetime": 1783493520,
                "headline": "Strength Seen in CRINETICS PHARM (CRNX): Can Its 98.7% Jump Turn into More Strength?"
              },
              {
                "id": 140837926,
                "url": "https://finnhub.io/api/news?id=a70293ebe98e19e67dedeb8cf9ce371a3c1d5aa0848d769bd645f7d54e878082",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Wall Street sees bigger upside in VKTX, with Koyfin’s average target implying 120% upside versus 99% for BCRX.",
                "category": "company",
                "datetime": 1783487516,
                "headline": "VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal?"
              },
              {
                "id": 140837513,
                "url": "https://finnhub.io/api/news?id=302924a36eab9926010fffab59b808557440262affead14cf63dfd8c0e1baeda",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Investors favored companies benefiting from biotech deals, rising power demand from AI data centers, and cost-cutting efforts to improve profits.",
                "category": "company",
                "datetime": 1783481690,
                "headline": "Why Did CRNX, D, BCRX Stocks Surge To 52-Week Highs Today?"
              },
              {
                "id": 140837469,
                "url": "https://finnhub.io/api/news?id=b41fefdad013a03f064cf0678a488c23051e8ccf264f74d11beba5bc943475a2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The drugmaker is paying up for a new growth engine. Is the price disciplined?",
                "category": "company",
                "datetime": 1783480800,
                "headline": "Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know."
              },
              {
                "id": 140837515,
                "url": "https://finnhub.io/api/news?id=988fe71e303ec83078bc381eddbb7fd02400f18abf469139ca5464ab1e83974a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics stock nearly doubled after Vertex agreed to buy it for $10 billion. What's behind the deal, and is it worth it?",
                "category": "company",
                "datetime": 1783480141,
                "headline": "Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout"
              },
              {
                "id": 140836545,
                "url": "https://finnhub.io/api/news?id=7ba3abe3ae1625e355c2830d91d3a21de9e5402e5d28ee8f3025463f835c5589",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.",
                "category": "company",
                "datetime": 1783461606,
                "headline": "Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note"
              },
              {
                "id": 140835479,
                "url": "https://finnhub.io/api/news?id=8280e2e479d67e2480a6b07e516a44aa2f83a2ce7e43ac27edbcf166b365c0cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (NasdaqGS:VRTX) agreed to acquire Crinetics Pharmaceuticals for US$10b. The deal adds a marketed rare disease drug and moves Vertex into endocrinology as a new business area. The transaction is positioned to expand Vertex's portfolio beyond its existing core franchises. Vertex Pharmaceuticals has built its business around treatments for rare and serious diseases, and the planned Crinetics acquisition marks a shift into endocrinology with an FDA approved therapy and...",
                "category": "company",
                "datetime": 1783455716,
                "headline": "Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology"
              },
              {
                "id": 140835480,
                "url": "https://finnhub.io/api/news?id=32f8fcb1eaad62c124d29a25a84e691fb7f1f29825e76b0b1eebbbb987ca4a72",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "BOSTON, July 07, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the \"Vertex Pharmaceuticals Second Quarter 2026 Earnings Call.\"",
                "category": "company",
                "datetime": 1783454400,
                "headline": "Vertex to Announce Second Quarter 2026 Financial Results on August 3rd"
              },
              {
                "id": 140835352,
                "url": "https://finnhub.io/api/news?id=cde7c44a0e7ab15b40a678d6dc96c3f9be5c0f283a2690eb28957cfa2f295b37",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S",
                "category": "company",
                "datetime": 1783453906,
                "headline": "Sector Update: Healthcare Stocks Gain Late Afternoon"
              },
              {
                "id": 140834318,
                "url": "https://finnhub.io/api/news?id=4e9ef5791e5b2a2d1c19e57073528d609a4e42146820cba80a95535569ffa69a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "An all-cash deal at $85 per share adds an FDA-approved acromegaly pill",
                "category": "company",
                "datetime": 1783450318,
                "headline": "Vertex Pays $10 Billion to Enter Rare Endocrine Disease"
              },
              {
                "id": 140833117,
                "url": "https://finnhub.io/api/news?id=6b103d3f540e5f36b2a1fe66606bdfcb34a21bef507ed05b89e2282c9c0ef2b1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) and Crinetics Pharmaceuticals (CRNX) said late Monday they have reache",
                "category": "company",
                "datetime": 1783445779,
                "headline": "Top Midday Gainers"
              },
              {
                "id": 140832952,
                "url": "https://finnhub.io/api/news?id=a07c9c4cef97cce487e30f32d0b1056e59bd7c136669ff319a0aef87895b94ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking. “There is a move in biotech that we have not ... Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”",
                "category": "company",
                "datetime": 1783441817,
                "headline": "Jim Cramer Calls Biotech “The Hottest Group in the Market” as He Predicts “Deals Are Going to Be Flooding the Market”"
              },
              {
                "id": 140831208,
                "url": "https://finnhub.io/api/news?id=f1ee1f2e8c1fd17d1633be73a2c1668c06c85cf4fbafeaf8fcc4f8d5c6c0829f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "All three major US stock indexes were down in late-morning trading Tuesday, with the Nasdaq Composit",
                "category": "company",
                "datetime": 1783439032,
                "headline": "Top Midday Stories: Amazon Seeking at Least $25 Billion From US Bond Sale; Fiserv Explores Sale of STAR Debit Network"
              },
              {
                "id": 140831571,
                "url": "https://finnhub.io/api/news?id=fd4cfb9cc3d3f9c492421fc560dd27520cdb70922e902008693b53b70a690777",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "One has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.",
                "category": "company",
                "datetime": 1783436212,
                "headline": "CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?"
              },
              {
                "id": 140831572,
                "url": "https://finnhub.io/api/news?id=a38981dea90aa6ee37cb87bf3739ffe86ace6009025274a29e968a0aacfd5895",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "H.C. Wainwright said Crinetics’ lead product Palsonify adds a meaningful commercial product and establishes endocrinology as Vertex’s fifth major business pillar.",
                "category": "company",
                "datetime": 1783432786,
                "headline": "Crinetics Acquisition Creates A ‘Fifth Commercial Pillar’ For Vertex, Says Analyst – Why HC Wainwright Sees A 24% Upside Potential In VRTX Stock"
              },
              {
                "id": 140831573,
                "url": "https://finnhub.io/api/news?id=bca90c08c5290d0b057aea4f48f97dd4c108c16a4c261af6221185093ff4e309",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.",
                "category": "company",
                "datetime": 1783430760,
                "headline": "VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout"
              },
              {
                "id": 140832339,
                "url": "https://finnhub.io/api/news?id=46c5e09411d8bcbed1515bf6da0dbfca71752d4b52eb881dd94a2e11b591e58c",
                "image": "https://image.cnbcfm.com/api/v1/image/108321360-17812891372026-06-12t182423z_83870851_rc2fslai0haj_rtrmadp_0_spacex-ipo-california.jpeg?v=1781289188&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "Here are some of the companies making headlines in midday trading.",
                "category": "company",
                "datetime": 1783428319,
                "headline": "Stocks making the biggest moves midday: SpaceX, GE Vernova, Crinetics Pharmaceuticals, Rivian & more"
              },
              {
                "id": 140830197,
                "url": "https://finnhub.io/api/news?id=cd09cc813c3c771f401b16333afdcc9fbe21d5fcde3dba55ef6ac7f8034d3b94",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday agreed to acquire Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) for $85 per share in cash, a total equity value of approximately $10 billion ($8.8 billion net of cash). Vertex expects to finance the acquisition using a combination of cash on hand and debt, supported by $4.5 billion of fully committed bridge financing. Vertex’s cash, cash equivalents, and total marketable securities as of March 31, 2026, were $13.0 billion. Read Also: Ver",
                "category": "company",
                "datetime": 1783427054,
                "headline": "Vertex Sees Over $5 Billion Peak Sales Potential From Crinetics Assets"
              },
              {
                "id": 140830198,
                "url": "https://finnhub.io/api/news?id=07741b6d9ed1ef64dc4112e20a34185f5ee95ea4ce76d750ea936acd7718c790",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal gives Vertex access to Palsonify, an oral acromegaly treatment, and atumelnant, a late-stage drug for congenital adrenal hyperplasia",
                "category": "company",
                "datetime": 1783426448,
                "headline": "Vertex Pharmaceuticals buying Crinetics for $10 billion"
              },
              {
                "id": 140829988,
                "url": "https://finnhub.io/api/news?id=3df760343f3160232fa4c72510327f355b63e953c2276f98c9574732cbf60b54",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "US equity futures were mostly pointing lower before the open Tuesday amid a broad sell-off in chip s",
                "category": "company",
                "datetime": 1783425801,
                "headline": "Equities Mostly Down Pre-Bell Amid Broad Chip Stock Sell-Off"
              },
              {
                "id": 140830040,
                "url": "https://finnhub.io/api/news?id=a5b5e4e6b022f571a62060f2e158d7ad3e421639d3865c95e74941408264af92",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.",
                "category": "company",
                "datetime": 1783425720,
                "headline": "Intel, Corning, Super Micro, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140834389,
                "url": "https://finnhub.io/api/news?id=f8120fe284a14c42bac7f9ab2142d824404d9d2fac35fa4ba4bb5bb2415a3974",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Outperform and raises the price target from $543 to $570.",
                "category": "company",
                "datetime": 1783424787,
                "headline": "RBC Capital Maintains Outperform on Vertex Pharmaceuticals, Raises Price Target to $570"
              },
              {
                "id": 140830042,
                "url": "https://finnhub.io/api/news?id=febf7ff565571596fdd064dd468b61ee976bf7804853ede03ddb2439477a3ade",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "(Bloomberg) -- US stock futures pointed to renewed weakness in technology shares after Samsung Electronics Co.’s earnings failed to satisfy investors, renewing pressure on chipmakers across global markets.Most Read from BloombergGreece Offers Bounty to Catch Ravenous Fish Lured by Warming SeaMicrosoft’s Xbox to Cut 3,200 Jobs, Divest Five Studios in Major OverhaulTwo Millennium Trading Pods Made About $3.7 Billion Last MonthSaudis Slash Main Oil Price to Rare Discount as Market DivesChina Senten",
                "category": "company",
                "datetime": 1783424433,
                "headline": "Tech Weakness Resumes After Samsung Misses Lofty AI Expectations"
              },
              {
                "id": 140830202,
                "url": "https://finnhub.io/api/news?id=2f55323c8d907b3bb40ad16b1905f12be42beb246018ca38ce78779ee8105690",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals  stock was surging on Tuesday after  Vertex Pharmaceuticals  said it had agreed to buy the biotech for $10 billion.  Vertex slid 1.2%.  Vertex said in a press release late Monday that it would buy Crinetics, which specializes in discovering and developing treatments for endocrine diseases, for $85 a share in cash.",
                "category": "company",
                "datetime": 1783423980,
                "headline": "This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal"
              },
              {
                "id": 140829214,
                "url": "https://finnhub.io/api/news?id=155cc42b2de9b601d259fb80cc11c90f2af57de44efa1c5cc9025478d67725b8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals (VRTX) agreed to acquire endocrine disease drugmaker Crinetics Pharmaceutical",
                "category": "company",
                "datetime": 1783422371,
                "headline": "Vertex Pharmaceuticals to Buy Crinetics in $10 Billion Deal"
              },
              {
                "id": 140829215,
                "url": "https://finnhub.io/api/news?id=6e62de35aca323dad3b8e253120c4385722cfe9e12ce4d1d34f033e9d96c5f74",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The acquisition is expected to close in the third quarter of 2026.",
                "category": "company",
                "datetime": 1783421730,
                "headline": "Vertex signs agreement to acquire Crinetics for $10bn"
              },
              {
                "id": 140829115,
                "url": "https://finnhub.io/api/news?id=e92e9ac4ecb469082683b27e468d358b772ad7fb4beab6459bfba2c132333c7f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "AI stocks take a beating, with South Korean memory-chip maker Samsung Electronics setting the tone for the broader market.",
                "category": "company",
                "datetime": 1783420500,
                "headline": "Samsung, Micron, Rivian, SpaceX, Crinetics, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 140829217,
                "url": "https://finnhub.io/api/news?id=f02fd4b54d91f01b651eff4be45b804765c5595587e6efb6cab6112e9600e9dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals stock has delivered a strong 112.8% return over the past three years, yet its valuation checks paint a mixed picture at the same time as investors weigh the agreed US$85 per share cash acquisition by Vertex Pharmaceuticals against the current market pricing. Over the last three years, Crinetics Pharmaceuticals has returned 112.8%, which puts recent gains in the context of a longer period of substantial shareholder returns. Vertex's planned US$10b cash acquisition,...",
                "category": "company",
                "datetime": 1783419426,
                "headline": "Crinetics (CRNX) Stock Could Be Overvalued After Its 113% Run"
              },
              {
                "id": 140830465,
                "url": "https://finnhub.io/api/news?id=e0b7e923d5f8e72f7db716b335ec70d8a45cdc7266f8d8f0ebc5eb2bc6f6bc3f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/464406694/image_464406694.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Q2 of 2026 started with a white-hot rally in the stock market, recovering its losses from the first quarter and setting several record highs throughout April (+10.4%) and May (+5.15).",
                "category": "company",
                "datetime": 1783419120,
                "headline": "Andrew Hill Investment Advisors' Q2 2026 Significant Positions"
              },
              {
                "id": 140830203,
                "url": "https://finnhub.io/api/news?id=75014b57a5eaea585df8853c5a378ed4fa238d1cdac808c53590a990dc26c001",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.",
                "category": "company",
                "datetime": 1783417140,
                "headline": "Vertex to acquire Crinetics in $10B foray into endocrine disease drugs"
              },
              {
                "id": 140829736,
                "url": "https://finnhub.io/api/news?id=e0487e79552e4d97446c9c81ed31eec4e8cb9d5ffc1b91a1f08090dd08181a5c",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247479872/image_2247479872.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click for more on VRTZX and CRNX stock.",
                "category": "company",
                "datetime": 1783415710,
                "headline": "Vertex To Acquire Crinetics For ~$10bn - What Investors Should Know"
              },
              {
                "id": 140828404,
                "url": "https://finnhub.io/api/news?id=200b597be5b9a31e4658b2e0199b272d24a4abcecad9634f0ee5e57ba86087b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and ability to generate solid returns.",
                "category": "company",
                "datetime": 1783412323,
                "headline": "3 Cash-Heavy Stocks with Promising Prospects"
              },
              {
                "id": 140832343,
                "url": "https://finnhub.io/api/news?id=a911d9e49ae3315a4eb192918505313e84961bf09078b0c391a960a3a6296fd3",
                "image": "https://image.cnbcfm.com/api/v1/image/108218536-1761745666275-gettyimages-2225995430-img_9520.jpeg?v=1761745710&w=1920&h=1080",
                "source": "CNBC",
                "related": "VRTX",
                "summary": "These are the stocks posting the largest moves in early trading.",
                "category": "company",
                "datetime": 1783409181,
                "headline": "Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more"
              },
              {
                "id": 140834391,
                "url": "https://finnhub.io/api/news?id=e4c8f1e19b3613fd9f004f952e570bc3810d5899aab6456735f82122c6df73c3",
                "image": "",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Baird  analyst Brian Skorney   maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Underperform and raises the price target from $330 to $350.",
                "category": "company",
                "datetime": 1783407241,
                "headline": "Baird Maintains Underperform on Vertex Pharmaceuticals, Raises Price Target to $350"
              },
              {
                "id": 140830640,
                "url": "https://finnhub.io/api/news?id=413aa9730aa18cba5d74ad66df0c1cbd03e28bf4c3ab224296e040b3b81b9294",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/07/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "VRTX",
                "summary": "Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) rose in pre-market trading after being acquired by Vertex Pharmaceuticals (NASDAQ: VRTX) for $85/share.",
                "category": "company",
                "datetime": 1783399774,
                "headline": "Why Crinetics Pharmaceuticals Shares Are Trading Higher By 99%; Here Are 20 Stocks Moving Premarket"
              },
              {
                "id": 140827624,
                "url": "https://finnhub.io/api/news?id=95526ead49aa5e48af33333c3ab040bf6a80ab2af0965c18abb7c6187c070e76",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "VRTX",
                "summary": "Vertex Pharmaceuticals Incorporated (VRTX) M&A Call July 6, 2026 4:30 PM EDTCompany ParticipantsSusie Lisa - Senior Vice President of Investor...",
                "category": "company",
                "datetime": 1783395149,
                "headline": "Vertex Pharmaceuticals Incorporated (VRTX) M&A Call Transcript"
              },
              {
                "id": 140825998,
                "url": "https://finnhub.io/api/news?id=8f7f628dd5cb5beeaf519272885c85adf58f740ac49355edfa785568f88e9d2a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "VRTX",
                "summary": "The deal values Crinetics at $85 per share in cash, representing a potential upside of about 100% from the stock’s closing price on Monday.",
                "category": "company",
                "datetime": 1783382832,
                "headline": "CRNX Stock Soars Nearly 100% After-Hours On Vertex's $10B Acquisition"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 143,
            "discarded_article_count": 109
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 20.7,
        "grade": "一般",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 2.2,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 2.2,
            "vcp_reason": "波幅收縮(14.2%→5.9%)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1761183.3333333333,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 1446830,
              "avg_vol_20": 1394090,
              "avg_vol_30": 1761183.3333333333,
              "range_pct_10": 0.0591078859969586,
              "range_pct_20": 0.0739003575685399,
              "range_pct_30": 0.1418713305825493,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.8215101588893832,
              "dist_to_20d_high": 0.0334285027742977,
              "down_shrink_days": 4,
              "breakout_level_20d": 500.76999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.4166302363856809
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.8,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "一般",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.696774998857044,
              "turnoverUsdM": 481.921564324356,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.VRTX",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 457.9236,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 5.4,
            "take_profit_price": 508.2315,
            "target_multiplier": 1.6,
            "technical_strength": 1.48,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 5.393549997714088,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.VRTX",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 100,
    "atr": {
      "atr": 13.0532,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.7
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "適中偏強",
      "score": 8,
      "value": 72.99
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.1281
    },
    "kdj": {
      "d": 49.72,
      "j": 69.26,
      "k": 56.24,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 47.64
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 10,
      "trend": "強流入",
      "value": 14241456,
      "recentSlope": 57665.6,
      "previousSlope": 2400
    },
    "rsi": 48.82,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 468.7729,
      "position": "SAR喺價下",
      "distancePct": 3.15,
      "previousTrend": "上升"
    },
    "ma50": 471.9792,
    "macd": {
      "macd": 0.8787331068930371,
      "trend": "中性偏多",
      "signal": 1.6449224595951346,
      "histogram": -0.7661893527020975
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 6,
      "value": 481.0205,
      "position": "連續1-2日>VWAP",
      "consecutiveAbove": 2
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.74,
      "score": 2,
      "avgVolume": 1338527,
      "currentVolume": 995644
    },
    "derived": {
      "ma20": 480.302,
      "ma50": 471.9792,
      "prevClose": 484.83,
      "avgVolume10": 1415794,
      "avgVolume20": 1338527,
      "changePercent": -0.17,
      "avgVolumeForScore": 1338527
    },
    "ma_cross": {
      "ma20": 480.302,
      "ma50": 471.9792,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 480.9255,
      "prevMa50": 471.0172,
      "spreadPct": 1.76,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 470.3966,
      "upper": 490.2074,
      "position": "上半部"
    },
    "rsi_short": 51.27,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.74
    }
  }
}

{
  "close": 484.03,
  "volume": 995644,
  "changePercent": -0.17
}